Difference between revisions of "Entospletinib (GS-9973)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "http://www.ncbi.nlm.nih.gov/pmc" to "https://www.ncbi.nlm.nih.gov/pmc") |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 5: | Line 5: | ||
===[[Chronic lymphocytic leukemia]]=== | ===[[Chronic lymphocytic leukemia]]=== | ||
| − | # Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. [ | + | # '''GS-US-339-0102:''' Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. [https://doi.org/10.1182/blood-2014-08-595934 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc4401348/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25696919/ PubMed] [https://clinicaltrials.gov/study/NCT01799889 NCT01799889] |
==Also known as== | ==Also known as== | ||
Latest revision as of 00:46, 1 July 2024
Mechanism of action
Spleen tyrosine kinase (SYK) inhibitor
Preliminary data
Chronic lymphocytic leukemia
- GS-US-339-0102: Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. link to original article link to PMC article PubMed NCT01799889
Also known as
- Code name: GS-9973